News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Analyst action
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Cormorant Asset Management, LP and Bihua Chen have reported a significant ownership stake of 9.17% in Bright Minds Biosciences Inc. This beneficial ownership translates to 900,000 Common Shares out of 9,812,061 shares outstanding as of May 15, 2026. The reporting persons share voting and …
Lindsay Corporation (NYSE:LNN) is set to trade ex-dividend shortly, with a payment of US$0.38 per share expected on August 31st. The company boasts a trailing yield of 1.3% and demonstrates strong dividend sustainability, paying out only 28% of earnings and 35% of free cash …
Bright Minds Biosciences (TSX:DRUG) is gaining attention due to progress in its lead neuroscience program, BMB, a selective serotonin receptor-targeting candidate for difficult-to-treat seizure disorders. The company reported positive topline results from its BREAKTHROUGH study, demonstrating anti-seizure activity and a favorable safety profile, and …
Adage Capital Management, L.P. and its affiliated entities have reported a beneficial ownership of 3.41% in Bright Minds Biosciences Inc. (DRUG) through a Schedule 13G/A filing. This stake, totaling 335,000 common shares, reflects shared voting and dispositive power among the reporting persons, including Robert …
Bright Minds Biosciences Inc (CN:DRUG) shares experienced a decline due to weakening investor sentiment in the biotechnology sector, coupled with increased development risks inherent in clinical-stage companies. The company, which focuses on psychedelic-inspired therapies for neurological and psychiatric disorders, faces challenges including clinical trial …
This article provides a stock analysis of Bright Minds Biosciences (CNSX:DRUG), highlighting its valuation, future growth prospects, past performance, and financial health. The company is trading significantly below its estimated fair value and its revenue is forecast to grow, but it faces risks such …
This article reports that an insider at Lindsay Corporation reduced their holdings by 38% over the past year. The significance of insider selling versus buying is also briefly discussed, suggesting that while buying often signals confidence, selling can be for various personal reasons.
First Trust Advisors LP significantly reduced its stake in Lindsay Corporation (NYSE:LNN) by 88.5% in the first quarter, selling over 174,000 shares but still retaining shares worth $2.7 million. Despite this reduction, institutional investors collectively own a substantial 89.94% of the company. Lindsay Corporation …
Bright Minds Biosciences Inc (CN:DRUG) saw its Canadian-listed shares jump 4.05% to C$114 on August 6, 2026, though this increase is attributed to extremely low trading volume (302 shares) rather than any new company news or market re-evaluation. The article emphasizes that the movement …
Bright Minds Biosciences (NASDAQ:DRUG) is scheduled to release its Q3 2026 earnings before market open on Thursday, August 13th. Analysts anticipate a loss of $1.2831 per share. The company previously reported a loss of $0.80 per share, exceeding analyst estimates by $0.06.
This article analyzes Bright Minds Biosciences Inc. (NASDAQ: DRUG) using AI models to provide trading strategies. It highlights a near-term strong sentiment influencing a mid-term neutrality toward a long-term positive bias, noting a mid-channel oscillation pattern. The analysis offers specific entry, target, and stop-loss …
Bright Minds Biosciences Inc. (DRUG) shows a current price of 77.770 USD with a 5.41% increase, and a market cap of 763.08M. Analyst ratings are predominantly "Buy" with a target price of 148.557 USD, indicating a 102.78% upside. The company is focused on developing …
Amundi reduced its stake in Lindsay Corporation (NYSE:LNN) by 4.5% in the first quarter, selling 12,250 shares but still retaining a significant holding. Other institutional investors also adjusted their positions, with several increasing their shares. Lindsay Corporation reported strong quarterly earnings, surpassing analyst expectations, …
Perceptive Advisors LLC reduced its stake in Bright Minds Biosciences (NASDAQ:DRUG) by 16% in the first quarter, selling 71,746 shares and retaining 377,544 shares valued at $27.5 million. Despite this, institutional investors collectively own about 40.5% of the company's stock, with several firms increasing …
Lindsay Corp. (LMF) announced its Q3 2024 earnings, reporting an actual EPS of CHF1.49, significantly beating the consensus of CHF0.95. However, the company missed revenue expectations, with actual revenue at CHF112.43M against an expected CHF116.62M, marking a 15.41% year-over-year decline. The earnings call took …
Lindsay Corp. (LNN) has approximately 1,279 employees worldwide as of March 2026, representing a 3.4% growth from 2023. The company is actively hiring, with 63 job postings in 2026, and its workforce is primarily concentrated in the United States, India, and Brazil. The average …
Lindsay Corporation (NYSE: LNN) reported total revenue of $676.37 million USD last year. The Irrigation segment was the top performer, generating $568.00 million USD, an increase from $513.90 million USD in the prior year. The United States was the largest geographical contributor, accounting for …
Vivo Capital LLC increased its stake in Bright Minds Biosciences (NASDAQ:DRUG) by 11.1% in the first quarter, now holding 557,172 shares valued at $40.7 million. Several other institutional investors also increased their positions, bringing total institutional ownership to 40.52%. The company reported better-than-expected quarterly …
Bright Minds Biosciences Inc. (NASDAQ:DRUG) has a consensus "Buy" rating from seven analysts, with an average 12-month price target of $143.83. The company, which is developing psychedelic-inspired treatments for mental health and neurodegenerative conditions, reported a quarterly loss of $0.80 per share, beating analyst …
This article provides historical data on dividends and stock splits for Bright Minds Biosciences Inc (DRUG). It indicates that no dividends have been distributed in the past five years. The company executed several 5-for-1 merger-related stock splits on June 22, 2023.
Search by ticker symbol or company name and select a result to open its chart.